These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 35636725)
21. Knock-out mouse for Canavan disease: a model for gene transfer to the central nervous system. Matalon R; Rady PL; Platt KA; Skinner HB; Quast MJ; Campbell GA; Matalon K; Ceci JD; Tyring SK; Nehls M; Surendran S; Wei J; Ezell EL; Szucs S J Gene Med; 2000; 2(3):165-75. PubMed ID: 10894262 [TBL] [Abstract][Full Text] [Related]
22. Feline Spongy Encephalopathy With a Mutation in the Takaichi Y; Chambers JK; Shiroma-Kohyama M; Haritani M; Une Y; Yamato O; Nakayama H; Uchida K Vet Pathol; 2021 Jul; 58(4):705-712. PubMed ID: 33779415 [TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical localization of aspartoacylase in the rat central nervous system. Madhavarao CN; Moffett JR; Moore RA; Viola RE; Namboodiri MA; Jacobowitz DM J Comp Neurol; 2004 May; 472(3):318-29. PubMed ID: 15065127 [TBL] [Abstract][Full Text] [Related]
25. A radiometric assay for aspartoacylase activity in cultured oligodendrocytes. Madhavarao CN; Hammer JA; Quarles RH; Namboodiri MA Anal Biochem; 2002 Sep; 308(2):314-9. PubMed ID: 12419345 [TBL] [Abstract][Full Text] [Related]
26. A mutation of aspartoacylase gene in a Turkish patient with Canavan disease. Eke GH; Iscan A; Cece H; Calik M Genet Couns; 2012; 23(1):9-12. PubMed ID: 22611636 [TBL] [Abstract][Full Text] [Related]
27. Comparative computational assessment of the pathogenicity of mutations in the Aspartoacylase enzyme. George Priya Doss C; Zayed H Metab Brain Dis; 2017 Dec; 32(6):2105-2118. PubMed ID: 28879565 [TBL] [Abstract][Full Text] [Related]
28. Canavan disease and the role of N-acetylaspartate in myelin synthesis. Namboodiri AM; Peethambaran A; Mathew R; Sambhu PA; Hershfield J; Moffett JR; Madhavarao CN Mol Cell Endocrinol; 2006 Jun; 252(1-2):216-23. PubMed ID: 16647192 [TBL] [Abstract][Full Text] [Related]
29. Pathological Bergmann glia alterations and disrupted calcium dynamics in ataxic Canavan disease mice. Hull VL; Wang Y; Burns T; Sternbach S; Gong S; McDonough J; Guo F; Borodinsky LN; Pleasure D Glia; 2023 Dec; 71(12):2832-2849. PubMed ID: 37610133 [TBL] [Abstract][Full Text] [Related]
30. New T530C mutation in the aspartoacylase gene caused Canavan disease with no correlation between severity and N-acetylaspartate excretion. Di Pietro V; Cavallari U; Amorini AM; Lazzarino G; Longo S; Poggiani C; Cavalli P; Tavazzi B Clin Biochem; 2013 Dec; 46(18):1902-4. PubMed ID: 24036223 [TBL] [Abstract][Full Text] [Related]
31. Ablating the Transporter Sodium-Dependent Dicarboxylate Transporter 3 Prevents Leukodystrophy in Canavan Disease Mice. Wang Y; Hull V; Sternbach S; Popovich B; Burns T; McDonough J; Guo F; Pleasure D Ann Neurol; 2021 Nov; 90(5):845-850. PubMed ID: 34498299 [TBL] [Abstract][Full Text] [Related]
32. Defective N-acetylaspartate catabolism reduces brain acetate levels and myelin lipid synthesis in Canavan's disease. Madhavarao CN; Arun P; Moffett JR; Szucs S; Surendran S; Matalon R; Garbern J; Hristova D; Johnson A; Jiang W; Namboodiri MA Proc Natl Acad Sci U S A; 2005 Apr; 102(14):5221-6. PubMed ID: 15784740 [TBL] [Abstract][Full Text] [Related]
33. Upregulation of N-acetylaspartic acid resulting nitric oxide toxicity induces aspartoacylase mutations and protein interaction to cause pathophysiology seen in Canavan disease. Surendran S Med Hypotheses; 2010 Dec; 75(6):533-4. PubMed ID: 20673702 [TBL] [Abstract][Full Text] [Related]
34. Expression of aspartoacylase activity in cultured rat macroglial cells is limited to oligodendrocytes. Baslow MH; Suckow RF; Sapirstein V; Hungund BL J Mol Neurosci; 1999; 13(1-2):47-53. PubMed ID: 10691291 [TBL] [Abstract][Full Text] [Related]
35. Extensive aspartoacylase expression in the rat central nervous system. Moffett JR; Arun P; Ariyannur PS; Garbern JY; Jacobowitz DM; Namboodiri AM Glia; 2011 Oct; 59(10):1414-34. PubMed ID: 21598311 [TBL] [Abstract][Full Text] [Related]
36. Structural modeling of p.V31F variant in the aspartoacylase gene. Krishnamoorthy N; Zayed H Metab Brain Dis; 2016 Jun; 31(3):723-6. PubMed ID: 26797702 [TBL] [Abstract][Full Text] [Related]
37. A new mouse model of Canavan leukodystrophy displays hearing impairment due to central nervous system dysmyelination. Carpinelli MR; Voss AK; Manning MG; Perera AA; Cooray AA; Kile BT; Burt RA Dis Model Mech; 2014 Jun; 7(6):649-57. PubMed ID: 24682784 [TBL] [Abstract][Full Text] [Related]
38. Increasing N-acetylaspartate in the Brain during Postnatal Myelination Does Not Cause the CNS Pathologies of Canavan Disease. Appu AP; Moffett JR; Arun P; Moran S; Nambiar V; Krishnan JKS; Puthillathu N; Namboodiri AMA Front Mol Neurosci; 2017; 10():161. PubMed ID: 28626388 [TBL] [Abstract][Full Text] [Related]
39. Aspartoacylase deficiency affects early postnatal development of oligodendrocytes and myelination. Mattan NS; Ghiani CA; Lloyd M; Matalon R; Bok D; Casaccia P; de Vellis J Neurobiol Dis; 2010 Nov; 40(2):432-43. PubMed ID: 20637282 [TBL] [Abstract][Full Text] [Related]
40. Novel mutation in an Egyptian patient with infantile Canavan disease. Zaki OK; El Abd HS; Mohamed SA; Zayed H Metab Brain Dis; 2016 Jun; 31(3):573-7. PubMed ID: 26613958 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]